The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.
T. Hansen
Other Remuneration - Roche
R. d. Christensen
Consultant or Advisory Role - Roche
Honoraria - Roche
R. F. Andersen
No relevant relationships to disclose
K. G. Spindler
Other Remuneration - Roche
A. Johnsson
No relevant relationships to disclose
A. K. M. Jakobsen
No relevant relationships to disclose